A method is disclosed for synthesizing molecular sieve SSZ-63 using 1-(decahydronaphthalen-2-yl)-1-methylpyrrolidinium cations as a structure directing agent.

A method is disclosed for synthesizing molecular sieve SSZ-63 using 1-(decahydronaphthalen-2-yl)-1-methylpyrrolidinium cations as a structure directing agent.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The present application relates to methods for leaching and extraction of precious metals. For example, the present application relates to methods of leaching gold, palladium and/or platinum from a substance comprising gold, palladium and/or platinum (such as a gold-containing ore or a platinum group metal (PGM) concentrate) using an organic solvent that is water-miscible or partially water-miscible.

The present application relates to methods for leaching and extraction of precious metals. For example, the present application relates to methods of leaching gold, palladium and/or platinum from a substance comprising gold, palladium and/or platinum (such as a gold-containing ore or a platinum group metal (PGM) concentrate) using an organic solvent that is water-miscible or partially water-miscible.

Provided herein are improved processes for convening C7-amino-substituted tetracylines to C7-fluoro-substituted tetracyclines as well as intermediates produced by or used in these processes. In one embodiment, a thermal fluorination method is provided in which a suspension comprising a non-polar organic solvent and a C7-diazo-substituted tetracycline hexafluorophosphate, hexafluoarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof is healed to provide a C7-fluoro-substituted tetracyline, or salt, solvate or combination thereof. In another embodiment, a photolytic fluorination is provided in which a solution comprising an ionic liquid and a C-7diazo-substituted tetracyline tetrafluoroborate, hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof is irradiated to provide a C7-fluoro-substituted tetracyline, or salt, solvate or combination thereof.

A method is disclosed for synthesizing a zeolite having the framework structure of SSZ-16 using a structure directing agent comprising a dication selected from one or more of 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpyrrolidinium]; and 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpyrrolidinium].

A method is disclosed for synthesizing a zeolite having the framework structure of SSZ-16 using a structure directing agent comprising a dication selected from one or more of 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpiperidinium]; 1,1′-(1,4-cyclohexylenedimethylene)bis[1-methylpyrrolidinium]; and 1,1′-(1,4-cyclohexylenedimethylene)bis[1-ethylpyrrolidinium].

Compounds having the chemical formula 1, ##STR00001##
a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.